Progenity to Present at Raymond James Life Sciences and MedTech Conference

SAN DIEGO--(BUSINESS WIRE)-- Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced today that the company will be participating in the Raymond James Life Sciences and MedTech Conference in New York, June 18 and 19.

Chief Executive Officer Harry Stylli, Ph.D., will present a corporate overview on Wednesday, June 19, from 10:55 AM to 11:25 AM EDT. Dr. Stylli and Eric d’Esparbes, Chief Financial Officer, will also participate in one-on-one meetings with investors.

About Progenity

Progenity, Inc., is a privately held biotechnology company with the mission of transforming healthcare to be more precise and personal. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics/epigenomics, proteomics, and microbiomics. These platforms feed an R&D pipeline of innovative products designed to improve patient outcomes in prenatal and perinatal healthcare settings, oncology, and gastroenterology. Progenity’s ultimate vision is to make precision medicine a reality by both diagnosing disease at its source and treating it with targeted therapies developed by the company. Progenity is headquartered in San Diego, California. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005354/en/